Borean Pharma reaches major technological milestone

Borean Pharma, the Danish biopharmaceutical and protein engineering company, has reached a key technological milestone by producing protein products with high affinity binding in the 100-200 picomolar range.

These results, the company says, demonstrate that its proprietary technology platform is capable of generating fully matured and optimised biopharmaceutical product candidates of a novel class in record time.

'This achievement is firm evidence that our antibody-analogue technology can produce products rivalling the best antibody products, both in terms of binding strength and specificity,' said Hans Christian Thogersen, Borean's chief scientific officer and founder. 'Most importantly, these results also show that Borean's antibody analogue molecules can be developed and fully matured with much higher efficiency and speed than anyone has ever managed.

'In terms of affinity-maturation of a product candidate, we have accomplished in four weeks what the antibody developers need 6-12 months to accomplish; and in terms of obtaining the first milligrams of pure final product, we have the advantage inherent to our bacterial expression/processing technology, which reduces that time frame from several weeks to several days.'

Borean Pharma was established with the aim of developing a new generation of pharmaceutical protein products. Its proprietary technology enables it to develop a new generation of highly efficacious antibody analogues that can be produced in E.coli. Borean believes that it can unleash the true potential of biologicals by providing efficacious and cost-effective protein-based antibody analogues.